Press Releases Year None2021202020192018201720162015201420132012201120102009 Date Title Views Dec 02, 2021 Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting PDF Version View HTML Nov 18, 2021 Epizyme Announces Updates to Its Board of Directors PDF Version View HTML Nov 12, 2021 Epizyme to Participate in Jefferies London Healthcare Conference PDF Version View HTML Nov 09, 2021 Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update PDF Version View HTML Nov 05, 2021 Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version View HTML Nov 04, 2021 Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414 PDF Version View HTML Nov 02, 2021 Epizyme Announces Date of Third Quarter 2021 Financial Results PDF Version View HTML Nov 01, 2021 Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making PDF Version View HTML Oct 07, 2021 Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version View HTML Sep 14, 2021 Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress PDF Version View HTML Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
